RecruitingNCT06658730

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance


Sponsor

W.L.Gore & Associates

Enrollment

1,500 participants

Start Date

Jun 19, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements.
  • Patient has been or is intended to be treated with an eligible registry device.\*
  • Patient is age ≥ 18 years at time of informed consent signature.
  • The intent to treat a patient with a Gore product must be made prior to soliciting for possible registry participation. If pre-procedure consent is not feasible due to emergent situation, consent prior to the time of discharge for the index procedure is acceptable.

Exclusion Criteria3

  • Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.
  • Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study\* within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.
  • The term "study" does not apply to other observational registries or quality improvement projects. Collection of Registry Device performance from interventional studies may be permissible provided device application is not investigational and there are no novel requirements that alter follow-up conduct (i.e., protocol-mandated interventions).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEndovascular

TEVAR - thoracic endovascular aortic repair


Locations(10)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Indiana University School of Medicine

Indianapolis, Indiana, United States

Duke University

Durham, North Carolina, United States

Rigshospitalet

Copenhagen, Denmark

Centre Hospitalier Universitaire Strasbourg

Strasbourg, France

Universitatsmedizin Frankfurt

Frankfurt, Germany

Regensburg University Hospital

Regensburg, Germany

Laiko General Hospital of Athens

Athens, Greece

Hospital Universitari de Bellvitge

Barcelona, Spain

Uppsala University

Uppsala, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06658730


Related Trials